| 1.815 0.005 (0.28%) | 04-30 12:23 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.35 | 1-year : | 2.75 |
| Resists | First : | 2.01 | Second : | 2.35 |
| Pivot price | 1.78 |
|||
| Supports | First : | 1.55 | Second : | 1.26 |
| MAs | MA(5) : | 1.86  |
MA(20) : | 1.71 |
| MA(100) : | 1.85 |
MA(250) : | 1.67 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 69.6 |
D(3) : | 73.7 |
| RSI | RSI(14): 57.3 |
|||
| 52-week | High : | 3.55 | Low : | 1.04 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACRV ] has closed below upper band by 37.4%. Bollinger Bands are 18.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.93 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.79 - 1.81 | 1.81 - 1.83 |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Thu, 30 Apr 2026
Acrivon Therapeutics (NASDAQ: ACRV) sets 2026 virtual meeting, director and auditor votes - Stock Titan
Thu, 23 Apr 2026
RA Capital boosts Acrivon (ACRV) stake to 28.8% after ATM share buy - Stock Titan
Thu, 23 Apr 2026
RA Capital funds add 3,888,888 Acrivon (ACRV) shares at $1.80 - Stock Titan
Tue, 21 Apr 2026
Acrivon (ACRV) Chief Legal Officer has 558 shares withheld for RSU taxes - Stock Titan
Wed, 15 Apr 2026
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 15 Apr 2026
New Acrivon employee gets stock options for 111,150 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 39 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 48 (%) |
| Shares Short | 2,190 (K) |
| Shares Short P.Month | 2,140 (K) |
| EPS | -2.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.3 % |
| Return on Equity (ttm) | -53.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -0.92 |
| PEG Ratio | 0 |
| Price to Book value | 0.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|